Clinical trial · Interventional
Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being tested for this study to treat warts and molluscum. Patients will be enrolled to test the efficacy and safety of this device. The duration of the study is 4-12 weeks depending on treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will receive standard of care therapy and/or NTAP depending on the number of lesions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Molluscum Contagiosum Skin Infection | — | UNRESOLVED | — |
| Verruca Vulgaris | Verruca Vulgaris | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Canthardin Collodion | Drug | — | UNRESOLVED |
| Cryotherapy | Device | — | UNRESOLVED |
| Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cold Atmospheric Plasma (CAP)
- description
- We are proposing a clinical trial of a floating electrode-dielectric barrier device (FE-DBD), a Cold Atmospheric Plasma (CAP) device for the treatment of Verrucae Vulgaris and Molluscum Contagiosum. While novel to the medical field, and especially to dermatology, there are already a number of publications regarding its use on human skin in adults and children. CAP devices utilize noble gases (such as helium) to deliver plasma state matter to the skin. As its name implies, the generated plasma stream is of near skin temperature and it exists on normal atmospheric pressure. During the generation of the plasma there is no electric contact with the patient. The treatment does not increase skin surface temperature and the used helium gas, the same as used for balloons, being a noble gas does not cause a chemical reaction with the skin. The flow of the gas is slow, thus there is no mechanical effect on the skin.
- interventionNames
- Device: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
- type
- ACTIVE_COMPARATOR
- label
- Cryotherapy
- description
- Current standard of care (SOC) for treating Verruca Vulgaris in Children is cryotherapy. Patients randomized to this arm of the study will receive SOC treatment for their identified condition.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Years
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * All patients from 4-21 years old with at least 1 lesion of either verruca vulgaris or molluscum contagiosum * Willingness of the participant and their guardian to provide consent when applicable Exclusion Criteria: * Unwillingness to participate in the study * Received any treatment on the lesion in the past month, as determined by review of participant medical record * Immunodeficiency as determined by review of participant medical record * Adverse response to prior treatments as determined by review of medical record * Signs of self-resolution as determined by study team members * Conditions that lead to excessive scarring as determined by study team members * Facial and genital lesions as determined by study team members
References
Publications (1)
- DERIVEDWalker CL, Shope CN, Andrews LA, Atherton KM, Beck T, Santa Lucia G, Fridman G, Friedman PC, Cotton CH, Wine Lee L. A randomized controlled trial analyzing nonthermal atmospheric plasma for the treatment of verruca vulgaris in pediatric patients. J Am Acad Dermatol. 2025 Jan;92(1):46-50. doi: 10.1016/j.jaad.2024.07.1522. Epub 2024 Aug 27. PMID 39197495